Exemestane (Aromasin) is an oral aromatase inhibitor used in selected breast-cancer treatment. NCI drug information. The plan depends on hormone receptors, ovarian function and previous treatment.
Confidence is high for the documented identity and attributed licence/safety instructions. This review does not establish an independent comparative-benefit verdict: commercial label outcomes are excluded, and educational pages do not clear their supporting trials.
- Exemestane is hormone-directed treatment, not menopausal HRT.
- Specialist use with ovarian suppression differs from the postmenopausal product licence.
- Bone health and interacting medicines need review.
- Extra tablets need immediate advice before symptoms.
- England prescription items measure one dispensing setting, not benefit or worldwide popularity.
Table of contents
- Evidence summary
- Names and indications
- Mechanism
- Ovarian function and combination care
- Bone health and symptom support
- England usage and trial finance
- Urgent symptoms and overdose
- Medicine interactions
- Pregnancy and breastfeeding
- Tablets, missed doses and driving
- Preclinical evidence and commercial interests
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Identity | NCI | Page receipts unclosed | Drug identity; not benefit. |
| Ovarian context | NCI | Underlying trials unclosed | AI alone differs from suppression. |
| Licensed use | UK SmPC | Seller | Scope; outcomes excluded. |
| Patient warnings | UK leaflet; US label | Sellers | Product-specific safety. |
| TEAM | Original protocol | Pfizer support | Design/finance only. |
| Usage | England Table 7 | Agency finance below | Items, not benefit. |
Names and indications
The UK licence covers postmenopausal ER-positive invasive early breast cancer after two to three years of tamoxifen, and advanced cancer progressing after anti-oestrogen therapy. UK licensed scope.
US advanced-cancer licence: progression after tamoxifen. US scope.
ER means oestrogen receptor; tumour testing guides endocrine care. Adjuvant means after surgery, neoadjuvant before. Advanced/recurrent disease is separate. Care distinctions. These words describe the treatment context, not a promised outcome.
NCI lists PNU 155971, FCE-24304 and NSC 713563 as exemestane development names. Alias record.
Mechanism
Exemestane irreversibly inhibits aromatase, lowering androgen-to-oestrogen conversion. Mechanism. Steroidal describes its structure, not a bodybuilding use.
Breast endocrine treatment differs from menopausal hormone replacement therapy. Treatment distinction.
Ovarian function and combination care
With functioning ovaries, an aromatase inhibitor requires ovarian suppression. NCI describes GnRH agonists with aromatase inhibitors in selected male advanced-breast treatment too. Ovarian-function boundary.
The Christie describes exemestane with goserelin/leuprorelin before menopause and in selected males. Specialist use. This does not rewrite the licence.
NCI describes everolimus plus exemestane for selected postmenopausal HR-positive, HER2-negative advanced breast cancer after letrozole or anastrozole. US combination context. Everolimus is a separate medicine; its monitoring and risks require a separate treatment plan. No combination-dose advice is supplied.
Bone health and symptom support
Assess bone risk and vitamin D/deficiency because bone loss/fractures are possible. Bone precautions. No universal supplement regimen is supplied.
Report joint pain, fatigue, mood/sleep problems. Layers may ease hot flushes; check menopause remedies first. Support. Persistent symptoms need help.
Disclose complementary products and practices to the cancer team; they should not replace or delay treatment. Non-replacement safety. This review establishes no independent exemestane-specific supplement benefit.
England usage and trial finance
England’s original FY2025/26 Table 7 records 185,116 exemestane prescription items, BNF code 0803041C0. Chemical-substance row 1024.
PCA is a community-dispensing publication. Publication setting. Hospital-issued prescriptions fulfilled in the community are included; hospital dispensary supplies are excluded. Individual indications are not recorded. Actual methodology.
Items are not unique patients or proof of response. A malignant-disease classification cannot establish the diagnosis behind each prescription. This English measure does not identify global popularity, hospital-wide oncology use or superiority over letrozole, anastrozole or tamoxifen.
The TEAM protocol describes a randomised, open-label international adjuvant comparison and explicitly records Pfizer support despite clinician leadership. Original design and funding. Its outcomes are excluded from the independent verdict. No numerical recurrence or survival advantage is presented.
Urgent symptoms and overdose
Contact the team straight away for jaundice, illness with itching/right-sided abdominal pain, or severe rash. Promptly report infection signs or unexplained bruising/bleeding. Current warnings. Follow the service’s emergency instructions.
Call 999 or your local emergency number for sudden throat/tongue swelling, serious breathing difficulty or collapse suggesting severe allergy. Emergency recognition.
After extra tablets, contact a doctor at once or go straight to emergency care; bring the pack. Urgent advice.
Do not wait to feel unwell. Immediate excess-tablet action.
For suspected harmful ingestion, obtain immediate emergency help. Do not drive yourself, induce vomiting or give food or drink while awaiting advice. Poisoning precautions.
If you cannot keep yourself or someone else safe, seek emergency help immediately. Immediate mental-health safety.
Medicine interactions
Avoid oestrogen-containing medicines. Rifampicin, carbamazepine, phenytoin and St John’s wort can reduce exposure. Interaction warning. Do not adjust tablets yourself.
Review all medicines and supplements with the pharmacist, including any added cancer drug. This list cannot clear every interaction.
Pregnancy and breastfeeding
The UK leaflet excludes pregnancy or possible pregnancy, breastfeeding and use before menopause. Restrictions.
An explicit specialist ovarian-suppression plan differs from AI treatment alone. Confirm which care pathway applies.
Where pregnancy is possible, the US label advises testing and effective contraception. No breastfeeding during treatment or for one month afterwards; human milk/infant-safety data are absent. Reproductive warning. Confirm product-specific precautions with the team.
Review liver/kidney impairment, hereditary sugar disorders and ingredient allergy; excipient restrictions are formulation-specific. Product precautions.
Tablets, missed doses and driving
Take Aromasin after a meal exactly as prescribed. Administration.
Missed tablet: take when remembered unless next dose nearly due; never double. Avoid driving/machinery if drowsy, weak or dizzy. Leaflet instructions.
Record symptoms, missed tablets and other medicines for the prescribing team. No personal switching or stopping sequence is provided.
Preclinical evidence and commercial interests
Animal reproductive findings do not establish human benefit or individual risk. Preclinical section.
Pfizer’s 2025 filing documents medicine sales, alliance/royalty income and debt financing, with New York executive offices. Actual parent filing.
Companies House records Pfizer Inc controlling at least 75% of Pfizer Limited’s shares and voting rights. Filed UK control. This is a recorded threshold, not a verified exact percentage. Product-specific receipts, ultimate investors and individual trial payments remain unclosed.
A commercial label has legal safety duties and a sales interest. A public educational source has clinical accountability but can summarise financially connected trials. These different roles explain the confidence statement; neither institution’s logo establishes an independently funded efficacy result.
Funding and source roles
Research funding at a glance
26 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: exemestane | Public/gift routes below; page/reviewer/trial receipts unclosed. | US; Bethesda. | Tier 2 education, provisional. | C — 19 December 2024; clinical accountability; no independent efficacy clearance. |
| NCI: drug dictionary | Public/gift routes below; page/reviewer/trial receipts unclosed. | US; Bethesda. | Tier 2 education, provisional. | C — Date unexposed; clinical accountability; no independent efficacy clearance. Dictionary cholesterol–pregnenolone wording unused. |
| NCI: breast endocrine therapy | Public/gift routes below; page/reviewer/trial receipts unclosed. | US; Bethesda. | Tier 2 education, provisional. | C — 23 September 2026; clinical accountability; no independent efficacy clearance. |
| NCI: everolimus | Public/gift routes below; page/reviewer/trial receipts unclosed. | US; Bethesda. | Tier 2 education, provisional. | C — 13 February 2025; clinical accountability; no independent efficacy clearance. |
| Aromasin UK SmPC | Pfizer Limited; ownership/revenue below. | UK; Sandwich, Kent. | Tier 4 seller. | D — May 2022; licence/safety duties, efficacy excluded. |
| Aromasin UK leaflet | Pfizer Limited; parent below. | UK; Pfizer Italia Srl, Ascoli Piceno, Italy. | Tier 4 seller. | D — January 2022; safety, efficacy excluded. |
| Aromasin US label | Pharmacia & Upjohn Company LLC; Pfizer registrant; finance below. | United States. | Tier 4 seller. | D — text December 2024; posted December 2025. Efficacy excluded. |
| Christie: exemestane | Trust accounts below; leaflet-author/study receipts unknown. | UK; Manchester. | Tier 2 provider context, provisional. | C — May 2026; clinical accountability. No numerical incidence, vaccine rule or supplement dose transferred. |
| Christie 2025/26 accounts | NHS contracts; research, education, services and charitable income; HCA private-care partnership. | United Kingdom. | Tier 3 financial filing. | B, provisional — selected notes 3.1/3.2 and partnership read; leaflet allocation and personal interests unclosed. |
| Christie: own index/footer | Trust finance separately traced. | Wilmslow Road, Manchester M20 4BX, UK. | Tier 3 identity self-report. | B — index dated May 2023; actual linked leaflet May 2026. Identity only. |
| Pfizer 2025 Form 10-K | Medicine sales, alliance/royalty revenue and debt financing. | Delaware corporation; New York executive offices. | Tier 4 commercial filing. | D — selected 2025 finance/HQ read. Product receipts, ultimate investors and trial allocations unclosed. |
| Pfizer Limited: Companies House | Pfizer Inc: at least 75% shares and voting rights. | UK company; US Delaware controller. | Tier 3 registry. | B, provisional — current filed control read; historical correspondence address. Not verified accuracy or exact ownership percentage. |
| TEAM original protocol | University of Birmingham sponsor; Pfizer financial support in participant sheets. | UK coordination; international study. | Tier 4 industry-funded project. | D — version 9, 11 May 2016. Individual author interests unclosed; outcomes excluded. |
| NHS: anaphylaxis | National-site policy below; page/reviewer receipts unclosed. | United Kingdom. | Tier 2 safety context, provisional. | C — 21 June 2023; June 2026 review deadline passed. Clinical accountability; no exemestane-event rate inferred. |
| NHS: poisoning | National-site policy below; page/reviewer receipts unclosed. | United Kingdom. | Tier 2 safety context, provisional. | C — 12 June 2025. Clinical accountability; no exemestane-event rate inferred. |
| NHS: urgent mental-health help | National-site policy below; page/reviewer receipts unclosed. | United Kingdom. | Tier 2 safety context, provisional. | C — 26 April 2023; April 2026 review deadline passed. Clinical accountability; no exemestane-event rate inferred. |
| NCCIH: complementary cancer care | Public/gift routes below; named reviewers and trial receipts unclosed. | US; Bethesda. | Tier 2 safety context, provisional. | C — October 2021. No independent exemestane-adjunct efficacy adopted. |
| NCI: budget | Congressional appropriations through HHS/NIH. | United States. | Tier 3 fiscal self-report. | B, provisional — 14 May 2026; enacted FY26 distinct from requests. Page/trial allocation unknown. |
| NCI: gifts | Gift Fund; research designations permitted, not proof of a named receipt. | US; Bethesda. | Tier 3 self-report. | B — 27 August 2025; donor/page/reviewer allocations unclosed. |
| NHSBSA: PCA 2025/26 | Agency finance below; no prescribing indication recorded. | England. | Tier 2 public statistics, provisional. | B — 4 June 2026; administrative accountability, not benefit. |
| PCA original Table 7 | NHSBSA dataset; agency trace below. | England community dispensing. | Tier 2 administrative data. | B — FY2025/26, row 1024, code 0803041C0: 185,116 items. Not patients or global use. |
| PCA original methods | NHSBSA compilation; finance below. | England. | Tier 2 statistics context. | B — June 2026 sections 1.1/1.2.3 read; community setting, not comparative outcomes. |
| NHSBSA 2025/26 accounts | DHSC-funded services and service charges; PCA allocation unknown. | UK; Newcastle upon Tyne. | Tier 3 financial report. | B — selected original pages 132–133/143 previously read; fiscal accountability, no trial clearance. |
| NHS content policy | DHSC funds website; policy rejects advertising/corporate sponsorship. | United Kingdom. | Tier 3 self-report. | B — October 2022; October 2025 deadline passed. Historical NHS Digital wording; not trust funding. |
| NCCIH appropriations | Congressional appropriations; displayed table ends FY2024. | US; Bethesda. | Tier 3 self-report. | B — actual table read; no FY2026 enacted total or page allocation inferred. |
| NCCIH Gift Fund | Voluntary donations/bequests; conditional or unconditional routes. | US; Bethesda. | Tier 3 self-report. | B — authority, not named receipts or reviewer/trial clearance. |
Frequently asked questions
Is exemestane the same as Aromasin? Aromasin contains exemestane. Drug identity. A different brand or generic still needs its own leaflet and ingredient check.
Can exemestane be used before menopause? Specialists may combine it with ovarian suppression. Current practice. Do not start it alone.
Can I breastfeed after my last tablet? US label: no breastfeeding for one month afterwards. Restriction. Obtain product-specific advice.
Does clinician leadership prove independent funding? No. TEAM’s original protocol records Pfizer support despite clinician leadership. Project funding.
Is a higher prescription count evidence that exemestane is better? No. Items describe dispensing, not comparative treatment outcomes or unique patients.
Sources and funding notes
Current served product documents were read with their actual text dates; web posting dates do not imply a new clinical revision.
The TEAM protocol is used only for design and financial provenance. Complete trial publications and individual declarations remain unclosed; no independent efficacy estimate is adopted.
The NCI dictionary’s cholesterol–pregnenolone mechanism wording is not adopted.
Provider numerical frequencies, temperature cutoffs, vaccine rules and supplement doses are excluded.
No individual prescription, prevention regimen, fertility calendar or automatic AI substitution is supplied.
- NCI: exemestane — Drug identity and US educational scope.
- NCI: drug dictionary — Development names only.
- NCI: breast endocrine therapy — Receptor and ovarian-function distinctions.
- NCI: everolimus — Specific combination context.
- Aromasin UK SmPC — Licence, mechanism and interaction warnings.
- Aromasin UK leaflet — Pregnancy/handling/overdose.
- Aromasin US label — Bone, reproductive and product instructions.
- Christie: exemestane — Symptoms, specialist use and support.
- Christie 2025/26 accounts — Provider funding channels.
- Christie: own index/footer — Provider address and current leaflet link.
- Pfizer 2025 Form 10-K — Parent revenue, financing and HQ.
- Pfizer Limited: Companies House — UK company control.
- TEAM original protocol — Trial design and financial provenance only.
- NHS: anaphylaxis — Emergency allergy recognition.
- NHS: poisoning — Immediate harmful-ingestion precautions.
- NHS: urgent mental-health help — Immediate safety-risk escalation.
- NCCIH: complementary cancer care — Disclosure and non-replacement safety.
- NCI: budget — Appropriation route.
- NCI: gifts — Separate authorised funding route.
- NHSBSA: PCA 2025/26 — Administrative publication setting.
- PCA original Table 7 — Exact chemical-substance row.
- PCA original methods — Coverage and indication limits.
- NHSBSA 2025/26 accounts — Agency revenue and identity.
- NHS content policy — National-site funding and editorial process.
- NCCIH appropriations — Historical public funding.
- NCCIH Gift Fund — Separate gift authority.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.